Intraocular Pharmacokinetic of Bevacizumab After a ingle Intravitreal Injection in Human Original Reearch Article

Purpoe To invetigate intraocular concentration and pharmacokinetic of bevacizumab after a ingle intravitreal injection in human. Deign Propective, noncomparative, interventional cae erie. Method We included 30 nonvitrectomized eye of 30 patient (age range, 43 to 93 year) diagnoed with clinically ignificant cataract and concurrent macular edema econdary to neovacular age-related macular degeneration, diabetic retinopathy, or retinal venou occluion in the ame eye. All patient received an intravitreal injection of 1.5 mg bevacizumab. Between one and 53 day after injection, an aqueou humor ample wa obtained during elective cataract urgery. Concentration of unbound bevacizumab in thee ample were quantified by enzyme-linked immunoorbent aay. Reult Concentration of bevacizumab in aqueou humor peaked on the firt day after injection with a mean concentration (cmax) of 33.3 μg/ml (range, 16.6 to 42.5 μg/ml) and ubequently declined in a monoexponential fahion. Nonlinear regreion analyi determined an elimination half-time (t1/2) of 9.82 day (R2 = 0.81). No ignificant difference between diagnoi ubgroup were noted. Concluion In human nonvitrectomized eye, the aqueou half-life of 1.5 mg intravitreally injected bevacizumab i 9.82 day.